Michelle Obama's Focus Upon Children's Cancer
Today Sept 17th, 2014 The First Lady of the United States of America, will be in Memphis, TN at St Jude Children's Research Hospital. Obviously many frontier oncolytic diagnostics and therapeutics will be discussed and showcased. However, I would doubt that Mrs. Obama, will depart St Jude's knowing that there is in FDA 1 at Dana Farber, a chemotherapy that might be without side effects and perhaps also be very effective against a myriad of cancer's. Kevetrin is not quite ready to be tested on children, however company management seems to think that a FDA stage 3 trial on retina-blastoma is possible. Imagine what marginal success against retina-blastoma would mean to cancer research, children and their parents. I would wager that some of the St Jude Doctor's that will be talking with Mrs. Obama, are aware of Kevetrin and what is happening at Dana Farber and Beth Israel.
Large Amounts Of New Money Available For Research
On September 8th, 2014 Stand Up To Cancer Canada, raised $109 million dollars for interdisciplinary cancer research. This brings their total to $369 million dollars since 2008. The 2014 take, increases the raise 28 million dollars over the 2012 amount. I would expect Canadian research to acquire clinical status in the immune activation P53 race. Keep an eye on the Jimmy Fund in the states.
When I survey the landscape of oncology, clinical trial testing, the current treatments available and the publics perception. I cannot think of a cancer compound with the combined trial success and near term clinical potential as Cellceutix' (OTCMKTS:CTIX) P53 activating Kevetrin.
Andrew Baum's 35 Billion Market
Now that IBM (NYSE:IBM) has decided to make P53 research their entry point into Biotechnology, such a move by Big Blue can only make Citigroup's Andrew Baum's, 35 billion dollar appraisal of immune system activating cancer drugs appear conservative.